Gil-Vicente Laura, Martín Germán, Soler Carme, Vila Anna, Saiz María Rocío, Navarro Paula F
Facultad de Veterinaria y Ciencias Experimentales, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain.
Hospital Veterinario UCV, Universidad Católica de Valencia San Vicente Mártir, 46018 Valencia, Spain.
Animals (Basel). 2024 Apr 12;14(8):1168. doi: 10.3390/ani14081168.
The use of omeprazole as a preventive treatment for gastrointestinal ulcers in veterinary medicine has been questioned during previous years. The aim of the present study is to assess the long-term effect of omeprazole on cobalamin and serum gastrin levels in healthy dogs. Eighteen healthy dogs were included: 10 in the control group and 8 in the omeprazole group. Three samples were collected: before starting the treatment (T), 30 days after the start of treatment (T), and at 60 days (T). The mean cobalamin value (ng/L) in the control group was 481.4 (±293.70) at T, 481.4 (±170.21) at T, and 513.2 (±174.50) at T. In the omeprazole group, the values were 424.62 (±161.57) at T, 454.5 (±160.96) at T, and 414.87 (±127.90) at T. No statistically significant changes were detected in cobalamin levels between the three-time period in both study groups. These results agree with previous findings in felines but contrast with human medicine studies. The median gastrin values (pg/mL) in the control group were 62.45 [30.17-218.75] at T, 76.06 [30.67-199.87] at T, and 63.02 [35.81-176.06] at T. The median gastrin value in the omeprazole group was 67.59 [55.96-101.60] at T, 191.77 [75.31-1901.77] at T, and 128.16 [43.62-1066.46] at T. Statistically significant differences were detected ( = 0.008), indicating an increase in gastrin levels after initiating treatment with omeprazole. In conclusion, the increased levels of gastrin observed in this population underscore the importance of conducting a comprehensive clinical assessment to identify potential gastrointestinal disorders, particularly in consideration of the usage of omeprazole as a preventive treatment.
过去几年,奥美拉唑在兽医学中作为胃肠道溃疡预防性治疗药物的应用受到质疑。本研究的目的是评估奥美拉唑对健康犬钴胺素和血清胃泌素水平的长期影响。纳入了18只健康犬:对照组10只,奥美拉唑组8只。采集了三个样本:治疗开始前(T₀)、治疗开始后30天(T₁)和60天(T₂)。对照组钴胺素的平均水平(ng/L)在T₀时为481.4(±293.70),T₁时为481.4(±170.21),T₂时为513.2(±174.50)。在奥美拉唑组,T₀时的值为424.62(±161.57),T₁时为454.5(±160.96),T₂时为414.87(±127.90)。两个研究组在三个时间段内钴胺素水平均未检测到统计学上的显著变化。这些结果与之前猫科动物的研究结果一致,但与人类医学研究结果相反。对照组胃泌素的中位数水平(pg/mL)在T₀时为62.45 [30.17 - 218.75],T₁时为76.06 [30.67 - 199.87],T₂时为63.02 [35.81 - 176.06]。奥美拉唑组胃泌素的中位数水平在T₀时为67.59 [55.96 - 101.60],T₁时为191.77 [75.31 - 1901.77],T₂时为128.16 [43.62 - 1066.46]。检测到统计学上的显著差异(P = 0.008),表明开始使用奥美拉唑治疗后胃泌素水平升高。总之,该群体中观察到的胃泌素水平升高凸显了进行全面临床评估以识别潜在胃肠道疾病的重要性,特别是考虑到将奥美拉唑用作预防性治疗时。